Optimal chemotherapy treatment for patients with advanced colorectal cancer

Rafał Stec; Lubomir Bodnar; Marta Smoter; Michał Mączewski; Cezary Szczylik

doi:10.5114/wo.2011.20529

eISSN: 1897-4309
ISSN: 1428-2526

Contemporary Oncology/Współczesna Onkologia

Current issue Archive Manuscripts accepted About the journal Supplements Addendum Special Issues Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

1/2011
vol. 15

Send email

Copy url:

abstract:

Review paper

Optimal chemotherapy treatment for patients with advanced colorectal cancer

Rafał Stec

,

Lubomir Bodnar

,

Marta Smoter

,

Michał Mączewski

,

Cezary Szczylik

Contemporary Oncology (2011) vol. 15; 1 (31–39)

DOI: https://doi.org/10.5114/wo.2011.20529

Online publish date: 2011/03/11

View full text Get citation

PlumX metrics:

Colorectal cancer (CRC) is one of the most common malignancies in the world. Each year one million new cases are diagnosed and about 500 000 people die of this disease. Due to the development of research in clinical oncology, many new antineoplastic agents are registered and available in the treatment of CRC, for example irinotecan, oxaliplatin, 5-fluorouracil, capecitabine, and the monoclonal antibodies bevacizumab, panitumumab and cetuximab. Introduction of molecularly targeted therapies caused prolongation of median time to progression of the disease as well as median overall survival. The best sequence of the therapeutic options for the achievement of the patients’ benefits and good tolerance of the treatment has not been established. This article contains a review of randomized phase II/III studies and registration trials regarding systemic treatment of CRC. The authors have attempted to translate the results of the studies into treatment optimization.

keywords:

Optimal chemotherapy treatment for patients with advanced colorectal cancer

Rafał Stec , Lubomir Bodnar , Marta Smoter , Michał Mączewski , Cezary Szczylik

colorectal cancer, palliative chemotherapy, bevacizumab, panitumumab, cetuximab

Rafał Stec

,

Lubomir Bodnar

,

Marta Smoter

,

Michał Mączewski

,

Cezary Szczylik